Consainsights logo

Anti Obesity Drugs Market Size, Share, Industry Trends and Forecast to 2030

Anti Obesity Drugs Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.


  • Published date -30th Jan 2024

  • Formats -PDF, CSV

  • Region -Global

What is the Market Size & CAGR of Anti Obesity Drugs market in 2021?

The global anti-obesity drugs market is projected to witness a steady growth with a Compound Annual Growth Rate (CAGR) of 5.8% from 2021 to 2027. It is expected that the market will reach USD 6.1 billion by the end of 2027. The increasing prevalence of obesity worldwide, coupled with the rising awareness about the health risks associated with obesity, is driving the demand for anti-obesity drugs. The market is witnessing significant investments in research and development to introduce innovative and more effective drugs to address the obesity epidemic.

COVID-19 Impact on the Anti Obesity Drugs Market

The COVID-19 pandemic has had a mixed impact on the anti-obesity drugs market. On one hand, the lockdown restrictions and closure of gyms and fitness centers led to a sedentary lifestyle for many individuals, resulting in weight gain and increased demand for anti-obesity drugs. On the other hand, the economic uncertainties and disruptions in healthcare services have affected the availability and access to these drugs, impacting the market growth. However, with the gradual reopening of economies and renewed focus on health and wellness, the market is expected to rebound in the post-pandemic period.

Anti Obesity Drugs Dynamics

The global anti-obesity drugs market is driven by factors such as the increasing prevalence of obesity, sedentary lifestyle, unhealthy dietary habits, and genetic predisposition to obesity. The market is also influenced by the growing awareness about the health risks associated with obesity, such as cardiovascular diseases, diabetes, and hypertension. Moreover, the shift towards preventive healthcare and wellness initiatives by governments and healthcare organizations is creating lucrative opportunities for market growth. However, stringent regulatory requirements, side effects of anti-obesity drugs, and the availability of alternative weight management solutions are some of the challenges faced by the market.

Segments and Related Analysis

The global anti-obesity drugs market is segmented based on drug type, distribution channel, and region. By drug type, the market is categorized into prescription drugs and over-the-counter drugs. Among these, prescription drugs hold the largest market share due to the need for medical supervision and personalized treatment plans for obesity management. The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies account for the highest market share owing to the availability of a wide range of anti-obesity drugs and specialized medical guidance.

By Region Analysis

In terms of regional analysis, North America dominates the global anti-obesity drugs market due to the high prevalence of obesity, advanced healthcare infrastructure, and increasing investments in research and development. Europe follows closely behind, driven by rising awareness about obesity-related health risks and proactive government initiatives to combat obesity. The Asia-Pacific region is expected to witness significant growth with the expanding obese population, changing lifestyle patterns, and increasing disposable income levels in emerging economies.

Key Market Players and Competitive Landscape

Some of the key players in the global anti-obesity drugs market include Novo Nordisk A/S, Orexigen Therapeutics Inc., GlaxoSmithKline plc, Arena Pharmaceuticals Inc., and Eisai Co. Ltd. These companies are actively involved in strategic collaborations, product launches, and acquisitions to strengthen their market position and expand their product portfolios. The competitive landscape of the market is characterized by intense competition, with players focusing on innovation and research to introduce novel anti-obesity drugs.

Recent Happenings in the Anti Obesity Drugs Market

In recent years, the global anti-obesity drugs market has witnessed several notable developments. For instance, Novo Nordisk A/S launched a new anti-obesity drug with improved efficacy and safety profiles. Arena Pharmaceuticals Inc. announced a strategic partnership with a leading biotechnology company to develop innovative treatments for obesity. GlaxoSmithKline plc invested in research and development initiatives to introduce advanced anti-obesity drugs with reduced side effects. These developments reflect the evolving landscape of the anti-obesity drugs market and the increasing focus on combating the obesity epidemic worldwide.

Frequently Asked Questions (FAQ):